Target intelligence / Profile preview

YTH N6-methyladenosine RNA binding protein 1 (YTHDF1)

Target
YTHDF1
Molecular classification
RNA-binding protein, Other
01

Overview

YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) is a key eukaryotic reader protein that specifically recognizes and binds to N6-methyladenosine (m6A)-modified cellular RNAs. By interacting with the translation machinery, such as eukaryotic initiation factor 3 (eIF3), YTHDF1 promotes the translation efficiency of its target mRNAs. In oncology, YTHDF1 is frequently overexpressed and acts as an oncogene across various malignancies, including colorectal, breast, and lung cancers, where it drives tumor proliferation, metastasis, and chemoresistance. Furthermore, YTHDF1 plays a critical role in shaping an immunosuppressive tumor microenvironment by suppressing dendritic cell cross-presentation and CD8+ T-cell infiltration, making it a highly attractive target for cancer immunotherapy. Emerging small-molecule inhibitors, such as SKLB-Y13 and salvianolic acid C, target the m6A-binding pocket of YTHDF1 to disrupt its interaction with methylated transcripts, thereby suppressing oncogenic translation and restoring anti-tumor immunity. However, therapeutic targeting of YTHDF1 must navigate potential safety concerns, as knockout models in mice have demonstrated cognitive and memory deficits, highlighting its physiological role in synaptic plasticity and learning.

Other names
YTHDF1YTH domain-containing family protein 1YTH domain family protein 1YTH domain family member 1DACA-1DACA1Dermatomyositis associated with cancer putative autoantigen 1
02

Mechanism of action

Inhibition of YTHDF1 by binding to its m6A-binding pocket, disrupting its interaction with m6A-modified mRNAs, and thereby suppressing the translation of oncogenic target proteins.

03

Biological functions

Cell proliferationImmune responseCell cycleApoptosisOther
04

Disease associations

CancerInflammationNeurodegenerative diseaseInfectionOther
05

Safety considerations

Cognitive impairmentLearning and memory defectsImpaired synaptic transmissionPotential systemic toxicity due to ubiquitous m6A regulationImpaired cardiomyocyte differentiationImpaired intestinal stem cell maintenance
06

Interacting drugs

SKLB-Y13

6 more in the full profile.

07

Biomarkers

YTHDF1 expression levelm6A RNA methylation levelCD8+ T cell infiltrationPRPF6 expressionTEAD1 expressionFZD5 expression

Beyond the preview

Go deeper on YTH N6-methyladenosine RNA binding protein 1 (YTHDF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on YTH N6-methyladenosine RNA binding protein 1 (YTHDF1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call